Accelrys, Inc.
Molecular modeling software maker updates restatement of finances
Published in Lab Business Week, March 12th, 2006
As mentioned in the earlier announcement, the company is in continuing discussions with the Securities and Exchange Commission with respect to the accounting treatment for certain contracts entered into after January 2004. The company at that time noted that the filing of its Quarterly Report on Form 10-Q for the quarter ending December 31, 2005 could be delayed as a result of the restatement process.
Due to the continuing discussions with the SEC, the company has now determined that it will be unable to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2006-03-12)
More Articles from Lab Business Week
- AEterna Zentaris, Inc.
Cancer drug developer's strategic shareholder exercises right to convert loan - Abbott
Pharma company reports record sales for 2005 - Access Pharmaceuticals, Inc.
Tumor therapy developer completes $5M convertible offering - Acologix, Inc.
Uremic pruritus drug maker closes second series C financing - Acorda Therapeutics
Multiple sclerosis drug developer prices initial public offering - Adolor Corp.
Pain management-focused company to make public offering of stock - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
